Tom Daulton, Mammotome CEO, Named ACG Dealmaker of the Year

CINCINNATI, May 21, 2013 /PRNewswire/ -- Tom Daulton, CEO of Mammotome, a division of Devicor Medical Products, has been named Dealmaker of the Year by the Cincinnati chapter of the Association for Corporate Growth (ACG). Daulton, who was nominated by another local top executive who is also a breast cancer survivor, led the purchase of the Mammotome® brand from Ethicon Endo-Surgery in March of 2010. Daulton will be presented with the award at the formal Deal Maker Awards program, presented by Huntington Bank, on May 22.

The ACG Deal Maker Awards program recognizes the significant achievements of corporations, entrepreneurs, and service providers who have been successful in their pursuit of corporate growth through acquisition, joint venture and/or divestiture transactions.

"Being recognized by an organization as well-respected as ACG is truly an honor," said Daulton.  "Being nominated by a breast cancer survivor made this award even more special to me and is a tribute to the more than 400 Mammotome employees around the world. Knowing that our work has helped someone in their fight against cancer is the greatest recognition of all."

Under Daulton's direction, Mammotome has continued to expand its global presence. In the last three years, the company has continued to develop and release clinically differentiated medical products and technologies that help physicians quickly and accurately diagnose breast cancer. Most recently, Mammotome officially launched its newest product – Mammotome® revolve™.  Mammotome® revolve™ received FDA approval and is available in the United States, Canada and Europe. The unique design of the Mammotome® revolve™ empowers clinical decision-making, increases procedural efficiency, and provides optimized sample retrieval through a patented tissue management technology. Other major new product milestones include the introduction of the tetherless vacuum-assisted biopsy device, Mammotome® elite™, which came to market in the spring of 2012. These products are designed for a faster and simpler procedural experience for both the physician and patient while providing superior tissue samples to help pathologists make a confident diagnosis.

As part of Mammotome's growth strategy, the company has invested heavily in infrastructure, opening offices in Paris, Rome, Seoul, Hamburg, Shanghai, and Tokyo. Recently, the company opened an advanced manufacturing facility in Tijuana, Mexico, and completed a state-of-the-art Global Training Center at the company headquarters in Cincinnati. In 2011, Devicor Medical Products completed the acquisition of the neoprobe® GDS portfolio of products. The company continues to maintain an active pipeline of potential acquisition opportunities.

About Devicor^® Medical Products, Inc.
Devicor Medical Products, headquartered in Cincinnati, Ohio, has more than 400 employees around the globe. The company is committed to advancing technology to help clinicians accurately diagnose breast disease, such as breast cancer, through minimally invasive procedures. Devicor's product portfolio includes the world-renowned Mammotome® Breast Biopsy System, neo2000® Gamma Detection System (GDS) and tissue markers (MammoMARK™, MicroMARK®II, and CorMARK™) used in breast disease diagnostic sampling and management. These products are sold in more than 50 countries around the world. Since its introduction in 1995, more than 3.6 million women have had a minimally invasive breast biopsy in stereotactic, ultrasound or MRI-guidance imaging using the Mammotome® Breast Biopsy System. For more information, please visit www.devicormedical.com or www.mammotome.com.

SOURCE Devicor Medical Products